Trials / Conditions / High Grade B-Cell Lymphoma, Not Otherwise Specified

High Grade B-Cell Lymphoma, Not Otherwise Specified

16 registered clinical trials studyying High Grade B-Cell Lymphoma, Not Otherwise Specified — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab NCT07097363	University of Washington	Phase 2
Recruiting	SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265	Verismo Therapeutics	Phase 1
Recruiting	Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients NCT06287398	Australasian Leukaemia and Lymphoma Group	Phase 2
Recruiting	A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409	IDP Discovery Pharma S.L.	Phase 1 / Phase 2
Active Not Recruiting	Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin NCT05202782	Northwestern University	Phase 2
Suspended	Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diag NCT04799275	National Cancer Institute (NCI)	Phase 2 / Phase 3
Unknown	Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphom NCT05097443	Shandong Provincial Hospital	Phase 3
Unknown	Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin NCT05164770	Shandong Provincial Hospital	Phase 3
Recruiting	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Agg NCT04231877	University of Washington	Phase 1
Withdrawn	Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphom NCT04285268	Rutgers, The State University of New Jersey	Phase 2
Active Not Recruiting	Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lympho NCT03984448	National Cancer Institute (NCI)	Phase 2 / Phase 3
Completed	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large NCT03742258	Northwestern University	Phase 1
Active Not Recruiting	Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lympho NCT03749018	David Bond, MD	Phase 2
Active Not Recruiting	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lympho NCT03038672	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chron NCT02153580	City of Hope Medical Center	Phase 1
Recruiting	Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia NCT01371630	M.D. Anderson Cancer Center	Phase 1 / Phase 2